HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.6%

Neg 0% Neu 86.6% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy and maintains $20 price target.